Fontanet Bijou
YOU?
Author Swipe
View article: Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials Open
Patients over 80 years (≥80 y.o.) with newly diagnosed diffuse large B-cell lymphomas (DLBCL) are underrepresented in clinical trials (CT). Use of synthetic control arms (SCA) could help to build innovative comparative trials. With this an…
View article: Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA
Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA Open
In this large real-world cohort of newly diagnosed DLBCL patients, age, occupational status, and patients' pathway were linked to very long delays to treatment. Interventions to streamline DTIs, especially for older and/or blue-collar or f…
View article: Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma Open
What is this summary about? This is a summary of the results of a study called ECHELON-3. This study compared a brentuximab vedotin (BV) combination (BV, lenalidomide, and rituximab) and a placebo combination (placebo, lenalidomide, and ri…
View article: Synthetic control arm from mixed clinical trials and real-world data from LYSA group for untreated diffuse large B cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials
Synthetic control arm from mixed clinical trials and real-world data from LYSA group for untreated diffuse large B cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials Open
Patients over 80 years (≥ 80 y.o) with newly diagnosed diffuse large B-cell lymphomas (DLBCL) are underrepresented in clinical trials (CT). Use of synthetic control arms (SCA) could help to build innovative comparatives trials. With this a…
View article: 254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY
254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY Open
View article: 101 | VALEMETOSTAT MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY RESULTS OF THE PHASE 2 VALYM STUDY FROM THE LYSA GROUP
101 | VALEMETOSTAT MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY RESULTS OF THE PHASE 2 VALYM STUDY FROM THE LYSA GROUP Open
View article: 52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY Open
View article: 379 | CAUSES OF DEATH IN POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: AN ANALYSIS OF THE FRENCH K‐VIROGREF REGISTRY
379 | CAUSES OF DEATH IN POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: AN ANALYSIS OF THE FRENCH K‐VIROGREF REGISTRY Open
View article: 598 | REDEFINING CLASSIFICATION ALGORITHM AND STAGING SYSTEM IN MARGINAL ZONE LYMPHOMA
598 | REDEFINING CLASSIFICATION ALGORITHM AND STAGING SYSTEM IN MARGINAL ZONE LYMPHOMA Open
View article: 436 | UPDATED EFFICACY/SAFETY OF BRUTON TYROSINE KINASE DEGRADER BGB‐16673 IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL: ONGOING PHASE 1 CaDAnCe‐101 RESULTS
436 | UPDATED EFFICACY/SAFETY OF BRUTON TYROSINE KINASE DEGRADER BGB‐16673 IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL: ONGOING PHASE 1 CaDAnCe‐101 RESULTS Open
View article: 441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS
441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS Open
View article: Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort
Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort Open
View article: Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)
Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma) Open
Background Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with l…
View article: A low lymphocyte‐to‐monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
A low lymphocyte‐to‐monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis Open
Summary The peripheral blood lymphocyte‐to‐monocyte ratio (LMR) has been shown to predict outcomes in follicular lymphoma (FL). Among 1018 patients from the RELEVANCE trial (for previously untreated, high tumour burden FL), the median LMR …
View article: Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma Open
PURPOSE In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safe…
View article: Data from The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Data from The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma Open
Purpose:Marginal zone lymphoma (MZL) is an uncommon non–Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation select…
View article: Supplementary Data from The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Supplementary Data from The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma Open
Supplement
View article: Real‐world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study
Real‐world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study Open
Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for real‐world data (RWD) evidence in MZL. Real‐w…
View article: Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study
Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study Open
View article: Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study Open
We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included acco…
View article: Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY Open
View article: Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort Open
Real-world data (RWD) are essential to complement clinical trial (CT) data, but major challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is a prospective noninterventional multicentric coh…
View article: Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study Open
The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with…
View article: P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: In an early-phase study, the combination of zanubrutinib plus obinutuzumab was well tolerated and associated with an early signal of efficacy in patients with …
View article: S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY. Open
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still …
View article: ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Open
Deep and durable responses with zanubrutinib plus obinutuzumab in patients with R/R FL.
View article: RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY Open
Introduction: Although in a phase III trial of extranodal MZL (EMZL) patients (pts) the combination of rituximab and chlorambucil had superior progression-free and event-free survival (PFS, EFS) compared to either drug given alone (Zucca e…
View article: A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial Open
International audience
View article: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY Open
Introduction: In an early-phase study, the combination of zanubrutinib plus obinutuzumab (ZO) was well tolerated and associated with an early signal of efficacy in patients (pts) with follicular lymphoma (FL) (Tam et al. Blood Adv, 2020). …
View article: REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.
REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort. Open
Background: Marginal Zone Lymphomas (MZL) are a heterogeneous group of lymphomas that include three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since most of the knowledge comes from clinical trials (with stri…